Cell Source

Cell Therapy Treatments Based on Immune Tolerance

Health Tech & Life Sciences
Active
Public Bnei Brak Founded 2011
Website ↗
Total raised
$21.5M
Stage
Public
Founded
2011
Headcount
20
HQ
Bnei Brak
Sector
Health Tech & Life Sciences

About

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented Veto Cell technology enables safe and selective tuning of immune responses. Veto Cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a proprietary mix of off-the-shelf, FDA-approved cytokines that change their characteristics and activate their inherent attacker-blocking capability. Once reintroduced into the body intravenously, they can perform a number of important functions. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating blood cancers such as lymphoma and nonmalignant congenital diseases such as sickle cell anemia.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companies